Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DM-3190
- Development stage
- Preclinical
- Lead developer
- DigmBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DM-3190 is an orally administered small molecule modulator of the tachykinin/substance receptor (TASR) pathway, also described as a modulator of serine and arginine rich splicing factor 10 (SRSF10). Developed by DigmBio, the compound is currently in preclinical development for the treatment of Parkinson's disease and other nervous system disorders. DM-3190 represents a novel therapeutic approach for neurodegenerative conditions by targeting specific splicing factors or tachykinin signaling to potentially mitigate disease progression, although its specific agonist or antagonist activity has not been publicly disclosed.
02
Targets
SRSF10 (Serine/arginine-rich splicing factor 10)NK (Neurokinin receptors)
Beyond the preview
Go deeper on DM-3190.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DM-3190.